Corbus (CRBP) Q2 Loss Beats Estimates

Corbus Pharmaceuticals (NASDAQ:CRBP), a clinical-stage biotechnology company focused on therapies for oncology and obesity, released its second-quarter 2025 results on August 5, 2025. The headline result was a GAAP net loss per share of $1.44 for Q2 2025, beating analysts’ consensus GAAP estimate of $(1.50) by $0.06 per share for Q2 2025. As expected, no revenue was reported as the company remains in precommercial development. Operating expenses rose significantly, increasing to $19.2 million in Q2 2025 from $11.0 million in Q2 2024 (GAAP), driven by higher research and development spending, but management emphasized that cash resources remain sufficient to fund operations through Q2 2027. The quarter reflected steady progress across development programs, key regulatory milestones. Source: Analyst estimates for the quarter provided by FactSet. Corbus Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of therapy candidates in oncology and metabolic disease. Its programs include three main drug candidates: CRB-701, an antibody-drug conjugate for cancer; CRB-601, a monoclonal antibody for immuno-oncology; and CRB-913, developed as a peripherally-acting therapy for obesity treatment. The company focuses on advancing these candidates through clinical trials and obtaining necessary regulatory approvals.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool